文献速递免疫规划卫生政策与健康促进

COVID-19疫苗特异性犹豫的相关因素与动态变化

The correlates and dynamics of COVID-19 vaccine-specific hesitancy.
PubMed 文献 · Vaccine · 2022-02-17

研究通过系列横断面调查实验,在超过6200名个体中检验对特定COVID-19疫苗的品牌差异犹豫。发现对阿斯利康和强生疫苗的犹豫高于辉瑞和莫德纳,且随罕见严重副作用争议而增长,在通常最支持大规模接种的人群中最强。

要点

  • 对阿斯利康和强生疫苗的犹豫高于辉瑞和莫德纳疫苗。
  • 比较性疫苗特异性犹豫随罕见严重副作用争议的出现而增长。
  • 多数受访者愿意等待数月以接种首选疫苗而非立即接种阿斯利康或强生疫苗。

核心结论

  • 对特定COVID-19疫苗存在品牌相关的比较性犹豫,且随时间增长。
  • 比较性疫苗特异性犹豫在通常最支持大规模接种的人群中最强。
  • 作者呼吁进一步研究疫苗特异性犹豫的决定因素与后果及沟通策略。

研究设计与样本

  • 系列横断面调查实验, examining more than 6,200 individuals in a series of cross-sectional surveys。

主要发现

  • 对阿斯利康和强生疫苗的犹豫高于辉瑞和莫德纳疫苗(若提供接种)。
  • 比较性犹豫随现场调查期间关于罕见严重副作用的争议而增长。
  • 多数受访者报告愿意等待数月以接种首选疫苗而非立即接种阿斯利康或强生疫苗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most work on COVID-19 vaccine hesitancy has focused on its attitudinal and demographic correlates among individuals, but the characteristics of vaccines themselves also appear to be important. People are more willing to take vaccines with higher reported levels of efficacy and safety. Has this dynamic sparked comparative hesitancy towards specific COVID-19 vaccines? We conduct a series of cross-sectional survey experiments to test for brand-based differences in perceived effectiveness, perceived safety, and vaccination intention. Examining more than 6,200 individuals in a series of cross-sectional surveys, we find considerably more reluctance to take the AstraZeneca and Johnson & Johnson vaccines compared to those from Pfizer and Moderna if offered, despite all vaccines being approved and deemed safe and effective by a federal regulator. Comparative hesitancy towards these vaccines grew over the course of fielding as controversy arose over their link to extremely rare, but serious side effects. Comparative vaccine-specific hesitancy is strongest among people who are usually most open to mass vaccination efforts. Its effects are substantial: most respondents reported a willingness to wait months for their preferred vaccine rather than receive either the AstraZeneca or Johnson & Johnson vaccine immediately. Our findings call for additional research on the determinants and consequences of COVID-19 vaccine-specific hesitancy and communication strategies to minimize this challenge.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Merkley E, Loewen PJ. The correlates and dynamics of COVID-19 vaccine-specific hesitancy. Vaccine. 2022. PMID: 35216840. doi:10.1016/j.vaccine.2022.02.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。